The Journal of Prevention of Alzheimer s Disease, Journal Year: 2024, Volume and Issue: unknown
Published: Jan. 1, 2024
Language: Английский
New England Journal of Medicine, Journal Year: 2024, Volume and Issue: 390(8), P. 712 - 722
Published: Feb. 21, 2024
Biomarker changes that occur in the period between normal cognition and diagnosis of sporadic Alzheimer's disease have not been extensively investigated longitudinal studies.
Language: Английский
Citations
151
Alzheimer s & Dementia, Journal Year: 2021, Volume and Issue: 18(4), P. 824 - 857
Published: Sept. 28, 2021
The Alzheimer's Disease Neuroimaging Initiative (ADNI) has accumulated 15 years of clinical, neuroimaging, cognitive, biofluid biomarker and genetic data, samples available to researchers, resulting in more than 3500 publications. This review covers studies from 2018 2020.
Language: Английский
Citations
110
Alzheimer s & Dementia, Journal Year: 2022, Volume and Issue: 19(1), P. 307 - 317
Published: Oct. 9, 2022
Abstract Introduction The Alzheimer's Disease Neuroimaging Initiative (ADNI) aims to validate biomarkers for disease (AD) clinical trials. To improve generalizability, ADNI4 enroll 50‐60% of its new participants from underrepresented populations (URPs) using biofluid and digital technologies. has received funding the National Institute on Aging beginning September 2022. Methods will recruit URPs community‐engaged approaches. An online portal screen 20,000 participants, 4000 whom (50‐60% URPs) be tested plasma APOE . From this, 500 undergo in‐clinic assessment joining ADNI3 rollover participants. Remaining (∼3500) longitudinal cognitive testing. add MRI sequences PET tracers. Project 1 optimize in AD Results Discussion generalizability results, use remote blood screening, continue providing clinical, biomarker, autopsy data investigators.
Language: Английский
Citations
84
EBioMedicine, Journal Year: 2022, Volume and Issue: 86, P. 104336 - 104336
Published: Nov. 7, 2022
Language: Английский
Citations
56
International Journal of Molecular Sciences, Journal Year: 2022, Volume and Issue: 23(5), P. 2486 - 2486
Published: Feb. 24, 2022
Alzheimer's Disease (AD) is one of the main neurodegenerative diseases worldwide. Unfortunately, AD shares many similarities with other dementias at early stages, which impedes an accurate premortem diagnosis. Therefore, it urgent to find biomarkers allow for diagnosis disease. There increasing scientific evidence highlighting between eye and structures CNS, suggesting that knowledge acquired in research could be useful AD. For example, retina optic nerve are considered part central nervous system, their damage can result retrograde anterograde axon degeneration, as well abnormal protein aggregation. In anterior segment, aqueous humor tear film may comparable cerebrospinal fluid. Both fluids enriched molecules potential biomarkers. Indeed, pathophysiology AD, characterized by cerebral deposits amyloid-beta (Aβ) tau protein, also present eyes patients, besides numerous structural functional changes observed structure eyes. all this suggests ocular have used either predictive values assessment or diagnostic tools.
Language: Английский
Citations
43
Alzheimer s & Dementia, Journal Year: 2023, Volume and Issue: 20(1), P. 652 - 694
Published: Sept. 12, 2023
The Alzheimer's Disease Neuroimaging Initiative (ADNI) aims to improve disease (AD) clinical trials. Since 2006, ADNI has shared clinical, neuroimaging, and cognitive data, biofluid samples. We used conventional search methods identify 1459 publications from 2021 2022 using data/samples reviewed 291 impactful studies. This review details how studies improved progression understanding trial efficiency. Advances in subject selection, detection of treatment effects, harmonization, modeling trials plasma biomarkers like phosphorylated tau showed promise for use. Biomarkers amyloid beta, tau, neurodegeneration, inflammation, others were prognostic with individualized prediction algorithms available online. Studies supported the cascade, emphasized importance neuroinflammation, detailed widespread heterogeneity disease, linked genetic vascular risk, co-pathologies, sex, resilience. Biological subtypes consistently observed. Generalizability results is limited by lack cohort diversity, an issue ADNI-4 address enrolling a diverse cohort.
Language: Английский
Citations
36
Neuropsychopharmacology, Journal Year: 2023, Volume and Issue: 49(1), P. 3 - 9
Published: Aug. 15, 2023
Abstract In contrast to most fields of medicine, progress discover and develop new improved psychiatric drugs has been slow disappointing. The vast majority currently prescribed treat schizophrenia, mood anxiety disorders are arguably no more effective than the first generation introduced well over 50 years ago. With only a few exceptions current work via same fundamental mechanisms action as first-generation agents. Here we describe reasons for this outline number areas research that involve greater reliance on experimental therapeutics utilizing recent advances in neuroscience better understand disease biology. We exemplify potential impact these focus with several examples novel agents have emerged which support our optimism newer, tolerated agents, horizon. Together existing newer could offer markedly functional outcomes millions people still disabled by disorders.
Language: Английский
Citations
34
Alzheimer s & Dementia, Journal Year: 2023, Volume and Issue: 20(1), P. 728 - 740
Published: Nov. 2, 2023
Abstract There is emerging evidence that amyloid beta protein (Aβ) and tau‐related lesions in the retina are associated with Alzheimer's disease (AD). Aβ hyperphosphorylated (p)‐tau deposits have been described were small spots visualized by vivo imaging techniques as well degeneration of retina. These changes correlate brain deposition determined histological quantification, positron emission tomography (PET) or clinical diagnosis AD. However, literature not coherent on these histopathological findings. One important reason for this variability methods interpretation findings across different studies. In perspective, we indicate critical methodological deviations among groups suggest a roadmap moving forward how to harmonize (i) histopathologic examination retinal tissue; (ii) methods, devices, algorithms; (iii) inclusion/exclusion criteria studies aiming at biomarker validation.
Language: Английский
Citations
28
Frontiers in Aging Neuroscience, Journal Year: 2023, Volume and Issue: 15
Published: April 18, 2023
Alzheimer’s disease (AD) is a progressive, neurodegenerative disorder that affects memory, thinking, behavior, and other cognitive functions. Although there no cure, detecting AD early important for the development of therapeutic plan care may preserve function prevent irreversible damage. Neuroimaging, such as magnetic resonance imaging (MRI), computed tomography (CT), positron emission (PET), has served critical tool in establishing diagnostic indicators during preclinical stage. However, neuroimaging technology quickly advances, challenge analyzing interpreting vast amounts brain data. Given these limitations, great interest using artificial Intelligence (AI) to assist this process. AI introduces limitless possibilities future diagnosis AD, yet still resistance from healthcare community incorporate clinical setting. The goal review answer question whether should be used conjunction with AD. To question, possible benefits disadvantages are discussed. main advantages its potential improve accuracy, efficiency radiographic data, reduce physician burnout, advance precision medicine. include generalization data shortage, lack vivo gold standard, skepticism medical community, bias, concerns over patient information, privacy, safety. challenges present fundamental must addressed when time comes, it would unethical not use if can health outcome.
Language: Английский
Citations
27
Mechanisms of Ageing and Development, Journal Year: 2023, Volume and Issue: 212, P. 111821 - 111821
Published: April 30, 2023
Language: Английский
Citations
27